Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells. - Test2 - elhamkhani - TriplyDB

Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells.

Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells.

http://www.wikidata.org/entity/Q35635226

about

Intelligent design: combination therapy with oncolytic viruses Adapting the Stress Response: Viral Subversion of the mTOR Signaling Pathway Stress Beyond Translation: Poxviruses and More Serotype-Specific Killing of Large Cell Carcinoma Cells by Reovirus.Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors.Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses A bioactive peptide analogue for myxoma virus protein with a targeted cytotoxicity for human skin cancer in vitro The battle over mTOR: an emerging theatre in host-pathogen immunity A whole-genome RNA interference screen for human cell factors affecting myxoma virus replication Gene therapy progress and prospects cancer: oncolytic viruses.Myxoma virus infection promotes NK lysis of malignant gliomas in vitro and in vivo.Rapamycin enhances the activity of oncolytic herpes simplex virus against tumor cells that are resistant to virus replication Myxoma virus-mediated oncolysis of ascites-derived human ovarian cancer cells and spheroids is impacted by differential AKT activity.Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo.Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin.In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells Myxoma virus sensitizes cancer cells to gemcitabine and is an effective oncolytic virotherapeutic in models of disseminated pancreatic cancer.Myxoma virus expressing human interleukin-12 does not induce myxomatosis in European rabbits Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer.Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs PI3K signaling regulates rapamycin-insensitive translation initiation complex formation in vaccinia virus-infected cells.Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded.Pharmacologic and chemical adjuvants in tumor virotherapy.The current status and future directions of myxoma virus, a master in immune evasion.Bugs and drugs: oncolytic virotherapy in combination with chemotherapy.Optimization and preclinical design of genetically engineered viruses for human oncolytic therapy.Tinkering with translation: protein synthesis in virus-infected cells.Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer.Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses.Virotherapy in cancer Oncolytic virotherapy for urological cancers.Investigation of cytotoxicity of negative control peptides versus bioactive peptides on skin cancer and normal cells: a comparative study.Pharmacological manipulation of the akt signaling pathway regulates myxoma virus replication and tropism in human cancer cells.Differential susceptibility of human cancer cell lines to wild-type tanapoxvirus infection.Myxoma virus: propagation, purification, quantification, and storage Myxoma virus expressing interleukin-15 fails to cause lethal myxomatosis in European rabbits.Myxoma virus combined with rapamycin treatment enhances adoptive T cell therapy for murine melanoma brain tumors.Identification of host DEAD-box RNA helicases that regulate cellular tropism of oncolytic Myxoma virus in human cancer cells.

P2860

Q24628227-DC279C58-D25B-4E47-AB96-D69283DAB4AB Q26700049-66C2FAD9-1918-4256-B43B-F88AD170A2BC Q26744471-ABAFCF40-53B0-4C87-B9BD-5951AD9E6EEF Q32183285-8EA9FBAD-3C99-4547-B97F-0BAD9B6009A7 Q33750535-62E878FB-8BD3-482D-ACD1-1DA193F4819D Q33895494-D1F991F5-2070-4750-8894-CA21E925B59A Q33924550-A5FEBAA5-6A5F-484A-8772-47F1C7A29C9F Q34340401-2BA0AC51-B6E3-485B-802D-D185A5775BF6 Q34426431-1F534220-B7FD-4EBD-B8B2-CE348BEEC931 Q34585582-289ED78E-3E08-4ED5-A663-62AFDD1ED1F9 Q34770611-E14E981C-CFF9-4AF3-A4A5-BECE98478507 Q34770719-216C513C-63D0-427F-8D07-EB812D5BC0A1 Q35097829-D85BEB7C-D9C3-4795-B1D1-65D7B058F703 Q35216344-E1E34F17-2C4C-4E42-BDF2-744DA16F10F6 Q35223458-4AFFD258-CC0E-450B-BAC0-EB6EF9D7D909 Q35234447-725DBBB3-2FC8-4D3C-A951-21CE6AE4FD4A Q35545752-3C8C0526-BFE3-41B9-A927-5DC1650BA15B Q35876172-3A242BB8-032A-4A23-B7F9-CF6FF593ADE5 Q36315458-290D182D-FC8A-4333-B1B5-34D96602DD06 Q36922264-42783799-6D11-42B7-B4E1-EB198D69D888 Q36943893-4EE5EF82-91A7-475B-B4BF-2F5C4BBBDFFE Q37031896-2A3EB968-22C6-47F8-AF1A-968E2A9E27F3 Q37145278-028F59CA-13E5-4AB9-BE81-10A612C54C25 Q37191007-15F31608-498F-43E3-A391-F3C366D790CB Q37492540-08BCE0B5-FBFF-49FE-82EB-4E156DFF3611 Q37887080-E2949108-958C-431C-91B4-EADD8506A30B Q37899223-BFD5A9CB-4BEE-48E3-8703-09A86C4DF1D9 Q38025696-0F4E03E0-84F6-477F-9F50-145FB8B67C0E Q38064834-23AF906B-8119-47E4-8396-1C883596AB88 Q38223419-6D4F9B85-ABC5-44E0-AA07-FD0D4048726B Q38237657-663DF381-BEA3-4F38-A06E-E45B5B6E668D Q38253646-6AFAA88A-3677-4B18-A917-A02C3D7C81BA Q38842126-FF7EDC98-C5D2-4578-BF11-0C9C6D81EA2D Q39292187-B030A9A6-205D-45D1-94D5-FC7FE1780B60 Q39610261-07963935-F93A-4D95-840C-D44E2CBBBFF3 Q39704822-7E9FF15E-863A-4C12-8F75-0EF9977427A1 Q39707862-3E01E69C-EA24-429C-9764-6E453EB46245 Q39995833-CD6AE14B-7A10-454F-A607-8D5E0551DA94 Q42118566-6051D120-8253-421E-9B11-A859C91A0E79 Q44837303-1BA52436-D3E1-4078-A604-DA21B7EB44E6

P2860

Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells.

http://www.wikidata.org/entity/Q35635226

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Oncolytic virotherapy synergis ...... tropism for human tumor cells.

@ast

Oncolytic virotherapy synergis ...... tropism for human tumor cells.

@en

type

label

Oncolytic virotherapy synergis ...... tropism for human tumor cells.

@ast

Oncolytic virotherapy synergis ...... tropism for human tumor cells.

@en

prefLabel

Oncolytic virotherapy synergis ...... tropism for human tumor cells.

@ast

Oncolytic virotherapy synergis ...... tropism for human tumor cells.

@en

P1433

Q35635226-338DC07A-F921-4500-A285-57F54356610F

P1476

Q35635226-AC102666-3BBE-425F-A8E3-086C7CBDF583

P2093

Q35635226-1442EE19-7AE8-40AF-8A79-95E565A3D9D6

Q35635226-3293288D-4060-4991-B157-3972DE67917E

Q35635226-7314FC2A-62AB-48B6-BFD8-E01556ECEECC

Q35635226-A7F88C7A-A26F-4C0C-9891-33ADC872F029

P2860

Q35635226-00FD993C-139E-41DC-8540-C4D49B45DCB7

Q35635226-01575F9D-F44A-4D9D-BBAA-10C562CDCABA

Q35635226-032AFD81-902D-4CAD-B49C-9FC16EB25A43

Q35635226-040CC610-28F6-4D96-AA9C-45557A5BE93C

Q35635226-04282B78-87A9-47A7-B361-F996CB835ED0

Q35635226-227CC09C-6557-4A03-AF0A-DDE7322379EB

Q35635226-24D46291-397B-4CF8-865F-3555D9700885

Q35635226-2E3AC4F9-103B-4BA0-9588-AFA5EC1458B7

Q35635226-3F4F0A40-C1DF-4224-8F07-7D4C1F9B2692

Q35635226-4CA55537-3CC8-4990-BADF-2A075322D038

P304

Q35635226-0461E321-39AD-42C5-A56A-C649C6E57533

P31

Q35635226-2EC58C3B-8D4D-4E6E-B6F3-3A065CEDC0D8

P356

Q35635226-7E014A87-556A-4F65-9180-3E55B74B9829

P407

Q35635226-974C423E-F7C0-4DF2-9825-57291FB8650D

P433

Q35635226-7469FA5F-7016-43D7-B1B0-D9D6963449A3

P478

Q35635226-AD0916D1-700E-4E7A-8CC9-7314A35309AF

P50

Q35635226-27529AEF-FD99-440B-8A18-67BD9DC69CFD

P577

Q35635226-DFA13B12-743D-46C5-AFB0-22CDDDF7A378

P5875

Q35635226-722AEB4A-5CD5-4875-867E-02E7623F6F49

P698

Q35635226-C64A1500-E021-42DA-97FB-FC50C7E8096E

P921

Q35635226-1BD08F13-2175-44C1-943F-0D992B2C71E9

P932

Q35635226-DAA7F6C0-FA25-4204-B983-4112A6848136

P356

P1433

Journal of Virology

P1476

Oncolytic virotherapy synergis ...... tropism for human tumor cells.

@en

P2093

John W Barrett

http://www.w3.org/2001/XMLSchema#string

Marianne M Stanford

http://www.w3.org/2001/XMLSchema#string

Steven H Nazarian

http://www.w3.org/2001/XMLSchema#string

Steven Werden

http://www.w3.org/2001/XMLSchema#string

P2860

AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1

Myxoma virus M-T5 protects infected cells from the stress of cell cycle arrest through its interaction with host cell cullin-1

A novel germline mutation of PTEN associated with brain tumours of multiple lineages

TOR, a central controller of cell growth.

Poxvirus tropism

Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases

The protein kinase B/Akt signalling pathway in human malignancy

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

Ras, PI(3)K and mTOR signalling controls tumour cell growth

Adventures with poxviruses of vertebrates.

P304

1251-1260

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.01408-06

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

81

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-11-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6689780

http://www.w3.org/2001/XMLSchema#string

P698

17108021

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

P932

1797522

http://www.w3.org/2001/XMLSchema#string